- Home
- WLGS vs PBM Comparison
WLGS vs PBM Comparison
Compare WLGS & PBM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLGS
- PBM
- Stock Information
- Founded
- WLGS 1981
- PBM 1994
- Country
- WLGS Hong Kong
- PBM Canada
- Employees
- WLGS N/A
- PBM N/A
- Industry
- WLGS Engineering & Construction
- PBM
- Sector
- WLGS Consumer Discretionary
- PBM
- Exchange
- WLGS Nasdaq
- PBM NYSE
- Market Cap
- WLGS 4.2M
- PBM 5.3M
- IPO Year
- WLGS 2023
- PBM N/A
- Fundamental
- Price
- WLGS $0.17
- PBM $3.77
- Analyst Decision
- WLGS
- PBM
- Analyst Count
- WLGS 0
- PBM 0
- Target Price
- WLGS N/A
- PBM N/A
- AVG Volume (30 Days)
- WLGS 1.6M
- PBM 58.2K
- Earning Date
- WLGS 05-20-2025
- PBM 05-20-2025
- Dividend Yield
- WLGS N/A
- PBM N/A
- EPS Growth
- WLGS N/A
- PBM N/A
- EPS
- WLGS 0.02
- PBM N/A
- Revenue
- WLGS $7,272,879.00
- PBM N/A
- Revenue This Year
- WLGS N/A
- PBM N/A
- Revenue Next Year
- WLGS N/A
- PBM N/A
- P/E Ratio
- WLGS $9.12
- PBM N/A
- Revenue Growth
- WLGS 66.93
- PBM N/A
- 52 Week Low
- WLGS $0.15
- PBM $0.41
- 52 Week High
- WLGS $9.66
- PBM $824.90
- Technical
- Relative Strength Index (RSI)
- WLGS 28.36
- PBM 43.08
- Support Level
- WLGS $0.15
- PBM $2.99
- Resistance Level
- WLGS $0.19
- PBM $4.80
- Average True Range (ATR)
- WLGS 0.02
- PBM 0.67
- MACD
- WLGS 0.13
- PBM 0.14
- Stochastic Oscillator
- WLGS 27.47
- PBM 41.87
About WLGS Wang & Lee Group Inc.
WANG & LEE Group Inc operates as an investment holding company. The firm conducts its primary operations through its indirectly wholly owned subsidiary WANG and LEE CONTRACTING LIMITED (WLHK). WLHK provides contract engineering, installation, and out-fitting of the following products and services: low voltage (220v/phase 1 or 380v/phase 3) electrical systems, mechanical ventilation and air-conditioning systems (MVAC), fire safety systems, and water supply and sewage disposal systems.
About PBM PSYENCE BIOMEDICAL LTD
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.